Ipsen announces it will acquire U.S. biotech Kartos Therapeutics to expand its oncology pipeline. Multiple outlets report the transaction is valued at up to $1.75 billion, including an upfront payment of $450 million. Quartz and the other reports describe Kartos as developing a treatment for myelofibrosis, a type of blood cancer, with the company’s drug in late-stage development. The deal structure indicates additional consideration beyond the upfront amount, though the specific performance conditions and timing are not detailed in the provided excerpts. The acquisition is presented as a strategic step by Ipsen to strengthen its presence in oncology, particularly in blood cancers. Overall, sources align on the buyer (Ipsen), the target (Kartos Therapeutics), the acquisition value range (up to $1.75 billion), and the initial $450 million figure. They also agree that Kartos’ key program focuses on myelofibrosis and is in late-stage development.